MAP
GYRE icon

Madison Avenue Partners’s Gyre Therapeutics GYRE Stock Holding History

Madison Avenue Partners’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-134,173
Closed -$1.79M – 19
2022
Q2 		$1.79M Buy
+134,173
New +$892K 0.37% 15

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Madison Avenue Partners's GYRE Position: Q3 2022 in Review

Madison Avenue Partners sold out of Gyre Therapeutics (GYRE) in Q3 2022, closing a stake of 134,173 shares — an estimated $1.79M sold.

Madison Avenue Partners first reported a position in GYRE in Q2 2022 and held it in 1 quarter. The position peaked at $1.79M in Q2 2022. 35 funds tracked by Wall St. Rank hold GYRE as of Q3 2022.

  • Madison Avenue Partners reported no remaining Gyre Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Madison Avenue Partners sold 134,173 Gyre Therapeutics shares in Q3 2022, an estimated $1.79M.
  • Madison Avenue Partners first reported a position in Gyre Therapeutics in Q2 2022 and held it in 1 quarter.
  • Madison Avenue Partners's Gyre Therapeutics position peaked at $1.79M in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2022.

Based on Madison Avenue Partners's 13F filing for Q3 2022, filed 14 Nov 2022.